AnaptysBio climbs on plans to split into two public companies

AnaptysBio

04/03/2026 16:27

** Shares of drug developer AnaptysBio ANAB.O rise 13.7% to over six-year high of $60.06

** Co said late on Tuesday it is splitting into two public companies by Q2 of 2026, potentially as early as late April, one to collect drug royalties and one to develop new medicines

** The new drug development company, First Tracks Biotherapeutics, trading under the ticker TRAX, will focus on treatments for autoimmune and inflammatory diseases

** AnaptysBio's current CEO, Daniel Faga, is expected to lead both companies initially

** ANAB also reported Q4 collab sales of $108.25 mln, compared to analysts est of $92.05 mln - LSEG

** AnaptysBio ended 2025 with $311.6 million in cash

** ANAB rose more than three-fold in 2025

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))